nitrapyrin has been researched along with Cancer of Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, M; Battalora, M; Bomann, WH; LeBaron, MJ; Peffer, RC; Rowe, RR; Tinwell, H; Werner, C | 1 |
| Butterworth, BE; Eisenbrandt, DL; Golllapudi, BB; Hardisty, JF; McConnell, EE; Seely, JC; Stebbins, KE; Swenberg, JA; Williams, GM; Yano, BL | 1 |
1 review(s) available for nitrapyrin and Cancer of Liver
| Article | Year |
|---|---|
Nitrapyrin: a scientific advisory group review of the mode of action and carcinogenicity in B6C3F1 mice.
Topics: Administration, Oral; Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Carcinoma, Hepatocellular; Cell Proliferation; Consensus; Dose-Response Relationship, Drug; Epigenesis, Genetic; Hepatocytes; Liver Neoplasms; Mice; Mice, Inbred Strains; Picolines; Risk Assessment | 2008 |
1 other study(ies) available for nitrapyrin and Cancer of Liver
| Article | Year |
|---|---|
Minimum datasets to establish a CAR-mediated mode of action for rodent liver tumors.
Topics: Animals; Biomarkers, Tumor; Constitutive Androstane Receptor; Cyclopropanes; Datasets as Topic; Fluorobenzenes; Liver Neoplasms; Mice; Picolines; Rats; Receptors, Cytoplasmic and Nuclear | 2018 |